Girish Dhall

Girish Dhall
Professor

Senior Scientist (C), O'Neal Comprehensive Cancer Center , School of Medicine
Senior Scientist, Neuro-Oncology , O'Neal Comprehensive Cancer Center
Professor (P), Pediatric - Hematology-Oncology , Pediatrics
Division Director, Pediatric - Hematology-Oncology , Pediatrics

Principal Investigator On

A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression awarded by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas awarded by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas - 12797sc awarded by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Gliomac-UFRA-317 awarded by THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

ACTION Trial- Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-Diagnosed Pediatric High-Grade Gliomas (Phase I) awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE

Investigator On

ACNS1831 - Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Children with Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) associated Low-Grade Glioma (LGG) (CRADA 02172) awarded by PUBLIC HEALTH INSTITUTE (PHI)

ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)

Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823 awarded by PUBLIC HEALTH INSTITUTE (PHI)

PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma, awarded by PUBLIC HEALTH INSTITUTE (PHI)

Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG awarded by PUBLIC HEALTH INSTITUTE (PHI)

Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG awarded by PUBLIC HEALTH INSTITUTE (PHI)

Per Case Reimbursement COG NCORP Research Base awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)

Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors awarded by PUBLIC HEALTH INSTITUTE (PHI)

Private Grant awarded by ONCOCEUTICS INC

Private Grant awarded by SPRINGWORKS THERAPEUTICS ^

Education And Training

Bachelor of Medicine & Surgery (MBBS), Maharashtra University of Health Sciences 1993

Full Name

Girish Dhall